Although it has been reported that Lenalidomide decreases the expression of ILT-2 on CLL cells, thus promoting NK cell proliferation and activation [117], today, there are no clinical studies evaluating the possible inhibition of HLA-G (or its receptors) in NK cell-based immunotherapy in hematological malignancies. The gene discussed is HLA-G; the disease is hematologic disorder.